JMP Securities analyst Joe Goodwin reiterates DocuSign (NASDAQ:DOCU) with a Market Outperform and maintains $84 price target.
Expert Ratings for Adaptimmune Therapeutics
Within the last quarter, Adaptimmune Therapeutics (NASDAQ:ADAP) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…